↓ Skip to main content

Aging

Reversal of cognitive decline: A novel therapeutic program

Overview of attention for article published in Aging, September 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 4,322)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Readers on

mendeley
778 Mendeley
Title
Reversal of cognitive decline: A novel therapeutic program
Published in
Aging, September 2014
DOI 10.18632/aging.100690
Pubmed ID
Authors

Dale E. Bredesen

Abstract

This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND). The first 10 patients who have utilized this program include patients with memory loss associated with Alzheimer's disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI). Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3-6 months, with the one failure being a patient with very late stage AD. Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance. Improvements have been sustained, and at this time the longest patient follow-up is two and one-half years from initial treatment, with sustained and marked improvement. These results suggest that a larger, more extensive trial of this therapeutic program is warranted. The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes. Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.

Timeline
X Demographics

X Demographics

The data shown below were collected from the profiles of 313 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 778 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 10 1%
Spain 4 <1%
Brazil 4 <1%
Canada 2 <1%
United Kingdom 2 <1%
Portugal 1 <1%
Germany 1 <1%
Belgium 1 <1%
Kazakhstan 1 <1%
Other 2 <1%
Unknown 750 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 122 16%
Other 110 14%
Student > Master 110 14%
Student > Bachelor 94 12%
Student > Ph. D. Student 69 9%
Other 175 22%
Unknown 98 13%
Readers by discipline Count As %
Medicine and Dentistry 225 29%
Agricultural and Biological Sciences 102 13%
Nursing and Health Professions 71 9%
Neuroscience 61 8%
Psychology 59 8%
Other 149 19%
Unknown 111 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 778. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 October 2024.
All research outputs
#26,795
of 26,728,046 outputs
Outputs from Aging
#5
of 4,322 outputs
Outputs of similar age
#139
of 264,484 outputs
Outputs of similar age from Aging
#1
of 15 outputs
Altmetric has tracked 26,728,046 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,322 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,484 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.